Overall rank by patents
#27,959
Across all tracked assignees
USPTO 2015–2025 USPTO PatentsView Foreign Corporation
Abbisko Therapeutics Co., Ltd.
USPTO PatentsView assignee record - 9 granted patents across 6 technology areas, active 2021–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS).
9
Total patents granted
6
CPC technology areas
9.4
Avg claims per patent
-
5-year filing velocity
The verdict
Abbisko holds 9 US patents across 6 technology areas, rank #27,959 of 50,000 tracked assignees.
- #27,959
- of 50,000 US assignees by volume
- Top 71%
- by Innovation Score (28.9/100)
- 9.4
- avg claims per patent
Portfolio overview
Abbisko Therapeutics Co., Ltd. has been granted 9 US utility patents between 2021 and 2025, placing Abbisko Therapeutics Co., Ltd. at rank #27,959 across all assignees tracked by PlainPatent. This portfolio spans 6 distinct Cooperative Patent Classification (CPC) subclasses, averaging 9.4 claims per patent with primary concentration in A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). As a Foreign Corporation, Abbisko Therapeutics Co., Ltd. is one of the more focused assignees in the PatentsView dataset. By volume, Abbisko sits between Aarbakke Innovation, A.s. (9 patents, rank #27,955) and Acandis Gmbh & Co. KG (9 patents, rank #27,963) - the closest US assignees by grant volume. The composite Innovation Score of 28.9/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Historical data spans 2021 through 2025, with 9 total grants over that period. Velocity comparisons require five years of historical filings to calibrate. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Abbisko Therapeutics Co., Ltd.'s 9.4 average claims per patent suggests focused, narrowly drawn claims typical of single-invention filings, while concentration in 6 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Abbisko Therapeutics Co., Ltd. against peers pursuing similar technology classes.
Who files at Abbisko's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Aarbakke Innovati…
AARBAKKE INNOVATION, A.S.
9 patents
- AB Medica S P A
AB MEDICA S.P.A.
9 patents
- Abaxx
ABAXX TECHNOLOGIES CORP.
9 patents
- ABB Turbo Systems
ABB Turbo Systems AG
9 patents
- Abclon
ABCLON INC.
9 patents
- ABM Italia S P A
ABM Italia S.P.A.
9 patents
- AC Avalanche
AC AVALANCHE, LLC
9 patents
- Acandis & KG
ACANDIS GMBH & CO. KG
9 patents
- Abbisko Therapeut… ◀
ABBISKO THERAPEUTICS CO., LTD.
9 patents
What this shows Abbisko holds 9 patents at rank #27,959, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Abbisko
By rank, the assignees closest to #27,959 in granted patent volume.
- Aarbakke Innovation, A.s. #27,955 · 9 patents
- AB Medica S.p.a. #27,956 · 9 patents
- Abaxx Technologies Corp. #27,957 · 9 patents
- ABB Turbo Systems Ag #27,958 · 9 patents
- Abclon Inc. #27,960 · 9 patents
- ABM Italia S.p.a. #27,961 · 9 patents
- AC Avalanche, Llc #27,962 · 9 patents
- Acandis Gmbh & Co. KG #27,963 · 9 patents
Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)
Other assignees with the most granted patents in Abbisko's primary technology class.
- The Regents Of The University Of California 1,387 in class
- Novartis Ag 1,071 in class
- Merck Sharp & Dohme Llc 889 in class
- Bristol-myers Squibb Company 879 in class
- Genentech, Inc. 789 in class
- The Board Of Regents Of The University Of Texas System 744 in class
- Hoffmann-la Roche Inc. 722 in class
- The United States Of America, As Represented By The Secretary, Department Of Health And Human Services 721 in class
Abbisko's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
29 Top 71% higher than 29% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2021–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2021 | 4 | 44.4% |
| 2022 | 2 | 22.2% |
| 2023 | 1 | 11.1% |
| 2024 | 1 | 11.1% |
| 2025 | 1 | 11.1% |
Which technologies does Abbisko Therapeutics Co., Ltd. patent most?
Top 6 of 6 technology areas
Patent Moat Analysis
Portfolio Volume Light
Tech Breadth Focused
Claim Depth Simple
Frequently Asked Questions
How many patents does Abbisko Therapeutics Co., Ltd. hold?
Abbisko Therapeutics Co., Ltd. holds 9 US granted patents filed between 2021 and 2025, spanning 6 technology areas.
What is Abbisko Therapeutics Co., Ltd.'s Innovation Score?
Abbisko Therapeutics Co., Ltd. has an Innovation Score of 28.9 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Abbisko Therapeutics Co., Ltd. focus on?
Abbisko Therapeutics Co., Ltd.'s top technology area is A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS) with 9 patents. The company has filed patents in 6 CPC subclasses total.
Is Abbisko Therapeutics Co., Ltd.'s patent filing rate increasing or decreasing?
Insufficient historical data is available to calculate a velocity trend for Abbisko Therapeutics Co., Ltd..
What does claim depth mean for Abbisko Therapeutics Co., Ltd.'s patents?
Abbisko Therapeutics Co., Ltd.'s patents average 9.4 claims each. This is relatively simple claim structure, typical for focused inventions.
How is the Abbisko Therapeutics Co., Ltd. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.
How to use this portfolio
Abbisko's 9 grants land it in the top 71% by Innovation Score, but volume alone doesn't tell you where the strength sits.
- Read that count against the largest US assignees before treating it as dominance - Abbisko ranks #27,959 of 50,000. Top 50 holders
- Most of this portfolio concentrates in A61P - see who else leads that technology area. A61P leaders
- Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.